Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

Phase 2RecruitingNCT07085169

Ruijin Hospital50 enrolled

Overview

This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer. Patients will be treated with trifluridine/tipiracil (17.5 mg/m2 dose orally twice daily, d1-10, every 14-days) plus bevacizumab (5mg/kg dose intravenously once at day 1, every 14-days). The study treatment will be administered until progression of disease, intolerable toxicity or withdraw of consent.

The treatment options as third-line therapy for metastatic colorectal cancer patients are limited. Trifluridine/tipiracil (TAS-102) plus bevacizumab has been approved in colorectal cancer for patients who are refractory to or intolerant of standard chemotherapy. However, the toxicity of trifluridine/tipiracil at standard dose a clinical concerned issue. Modifications of dose and treatment cycle of trifluridine/tipiracil have been investigated, and show promising effect to reduce the toxicity. In this study, patients with refractory metastatic colorectal cancer who have disease progression after at least 2 standard regimens will be treated with low-dose trifluridine/tipiracil plus bevacizumab. Trifluridine/tipiracil will be given at a 17.5 mg/m2 dose orally twice daily in a 14-day cycle consisting of 10 treatment days/4 rest days. Bevacizumab will be given at a 5mg/kg dose intravenously once at day 1 in a 14-day cycle. This regimen will be administered until progression of disease, intolerable toxicity or withdraw of consent.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Eligibility

Sex: ALLMin age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. age over 60 years old, male and female 2. histologically confirmed adenocarcinoma of the colon or rectum 3. patients with metastatic or advanced unresectable diseases who had received two or more previous chemotherapy regimens or intolerance to last regimen 4. with or without measurable lesions 5. ECOG 0 to 2, expected survival time over 3 months 6. Enough organ functions that can tolerate treatment: Absolute neutrophil count (ANC) ≥1.5x109/L, White blood count ≥3.5x109/L, Platelets ≥75x109/L, Hemoglobin (Hb) ≥80g/L, ALT/AST ≤2.5x ULN (for patient with liver metastasis ALT/AST ≤5x ULN), Serum bilirubin ≤1.5x ULN, Serum creatinine ≤1.5x ULN. 7. Signed informed consent and willing to follow the study protocol Exclusion Criteria: 1. symptomatic metastases of central nervous system 2. other primary malignancies 3. uncontrollable comorbidities, such as hypertension, thrombotic diseases, chronic kidney disease 4. organ functions that cannot tolerate study treatment 5. bowel obstruction or other conditions affecting oral administration 6. allergic to study medication 7. other conditions that patients are unsuitable for this study assessed by the investigators

Outcomes

Primary Outcomes

6-month progression-free survival rate

Defined as the proportion of patients who remain free from disease progression (as per RECIST criteria) or death for at least 6 months following initiation of study treatment.

Time frame: 6 months

Secondary Outcomes

Adverse events

Time frame: through study completion, an average of 1 year

Objective response rate

Time frame: up to 16 weeks

Progression free survival

Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Overall survival

Time frame: From date of enrollment until the date of death from any cause, assessed up to 100 months